PAR 8.00% 23.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-740

  1. 1,291 Posts.
    lightbulb Created with Sketch. 1314
    I am definitely not intelligent enough to keep up as well as you guys, but on the comment on stemcell trial's only being effective on young, healthy patients, doesn't that fly in the face a little of what another Australian company is seeking to establish in Melbourne?

    It seems there are now a couple of trials and results that require some further analysis. The Pfizer one seems to be quite easy to understand (and know that PAR is superior), but the one above I think requires some further understanding.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.